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Abstract
Purpose: To determine the efficacy and safety of topical bevacizumab treatment in patients with ocular surface
squamous neoplasia (OSSN).
Methods: Six eyes of 6 patients with primary OSSN confirmed by impression cytology received topical 5mg/
mL bevacizumab 4 times daily for a period of 8 weeks. Patients were evaluated in 2-week intervals. Digital
photography images were obtained at each visit and changes in the size of the lesions were analyzed by image
analysis software.
Results: The mean age of the patients was 66 – 13 (–SD) years. Four tumors were nasal in origin and 2 tumors
were temporal. The mean reduction observed in the lesion area was 43%– 24.2% (range, 20%–71%) in the first
month and 68%– 29.7% (range, 42%–100%) in the second month when compared with the baseline area. Four
patients required tumor excision at the end of the treatment period. Surgical treatment was not necessary in 2
patients due to complete disappearance of the tumor, which was confirmed by impression cytology. The visual
acuity was stable in all patients and no systemic or visual side effects were observed during the study period.
Conclusions: Topical bevacizumab is effective as a neoadjuvant therapy combined with surgical excision for
the treatment of OSSN. Topical bevacizumab may be used before surgery to decrease the size of the excision.
Excision may be unnecessary in responsive patients.
Introduction
Ocular surface squamous neoplasia (OSSN) is adysplasia of the conjunctival, limbal, or corneal epi-
thelium.1 It is the most common nonpigmented tumor of the
conjunctiva.2 OSSN is described as a relatively low-grade
malignancy because invasive disease is uncommon and
tends to be preceded by dysplasia and carcinoma in situ.1
However, a lack of appropriate and effective treatment for
OSSN can result in malignant changes, followed by local
invasion and, rarely, metastasis. OSSN includes conjuncti-
val and/or corneal intraepithelial neoplasia, intraepithelial
carcinoma of the conjunctiva, and conjunctival squamous
cell carcinoma.3
Treatment modalities include combinations of excision,
cryotherapy, and topical chemotherapy, including 5-flourouracil
(5-FU), mitomycin C (MMC), and interferon alpha-2b (IFN-
a2b).2 Surgical excision with adequate margins and ad-
junctive cryotherapy is a well-established treatment for
OSSN, although this is an invasive option with numerous
disadvantages. Chemotherapeutic agents can be used as
primary or adjunctive therapy.4 A review of individual
studies reveals similar efficacy between MMC, 5-FU, and
IFN-a2b.5 The cumulative and delayed ocular surface
toxicity of MMC, resulting in ocular irritation, conjunc-
tival hyperemia, and punctate keratopathy, and the com-
monly observed side effects of 5-FU, such as lid toxicity,
superficial keratitis, and corneal epithelial defects, make
these agents less preferred in the treatment of OSSN.6,7
Interferon-a2b has a better toxicity profile with occasional
flu-like symptoms and rare ocular surface irritation.
However, the high cost remains a major disadvantage.8
Antivascular endothelial growth factors (anti-VEGFs)
have been increasingly used for a range of cancers, including
other epithelial cancers of the head and neck, with the goal of
depriving the tumor of its vascular tissue. Bevacizumab
(Avastin; Genentech, Inc.), a full-length humanized mono-
clonal anti-VEGF antibody that was initially approved by the
FDA for the treatment of patients with colorectal cancer,
found off-label clinical implications in ophthalmology for the
successful treatment of age-related choroidal neovascular-
ization, proliferative and nonproliferative diabetic retinopa-
thy, neovascular glaucoma, and anterior segment neovascular
disorders.9–11
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Subconjunctival anti-VEGF agents have been used in a
few studies, for primary or recurrent OSSN, mostly with
favorable clinical results and without any ocular or systemic
side effects.12–15 However, the efficacy of topical anti-
VEGF treatment for OSSN was not evaluated previously.
The aim of this study was to determine the efficacy and
safety of topical bevacizumab treatment in patients with
OSSN.
Methods
The study was conducted in accordance with the De-
claration of Helsinki and approved by the Institutional Re-
view Board of Baskent University. Patients were given
detailed information regarding the off-label use of bev-
acizumab before treatment and informed consent was ob-
tained from each patient.
Six eyes of 6 patients with primary OSSN confirmed by
impression cytology received topical 5mg/mL bevacizumab
4 times daily for a period of 8 weeks. Patients with a history
of medical or surgical treatments were excluded from the
study. Regional metastasis was ruled out in all patients by
palpation of the cervical and periocular areas and by mag-
netic resonance imaging. Excisional biopsy of the remaining
tumor and cryotherapy of the conjunctival borders were
performed at the end of the topical treatment period, if
necessary.
Bevacizumab eye drops were aseptically prepared in the
hospital pharmacy by diluting the commercially available
intravenous bevacizumab (Avastin) solution (25mg/mL)
with sterile saline to a concentration of 5mg/mL, as previ-
ously described.16,17
Patients were evaluated in 2-week intervals. A complete
ophthalmological examination was performed and digital
photography images were obtained at baseline and at each
follow-up visit. Changes in the size and extent of the lesions
were analyzed by image analysis software (ImageJ 1.44p
Wayne Rasband; National Institutes of Health) using the
standardized digital slit-lamp photographs (32· magnifica-
tion). The lesion area was calculated in terms of pixels. The
percentage decrease in the area was calculated by the fol-
lowing formula: (baseline surface–post-treatment surface)/
baseline surface ·100.
Data were tabulated and analyzed using customized data-
base software (SPSS, Inc.). Correlations between data were
analyzed using the Wilcoxon signed-rank test. A P value less
than 0.05 was considered statistically significant.
Results
The mean age of the patients (4 men and 2 women) was
66 – 13 (–SD) years. Four tumors were nasal in origin and 2
tumors were temporal. The mean reduction observed in the
lesion area was 43% – 24.2% (range, 20%–71%; P = 0.026)
in the first month and 68%– 29.7% (range, 42%–100%;
P = 0.026) in the second month when compared with the
baseline area. Reduction in the tumor size was observed
both in the conjunctival and corneal portions of the tumors
(Fig. 1). Four patients (66.7%) required tumor excision at
the end of the treatment period, and histological examina-
tion revealed conjunctival intraepithelial neoplasia in all of
these patients. Surgical treatment was not necessary in 2
patients (33.3%) due to complete disappearance of the tu-
mor, which was confirmed by impression cytology (Fig. 2).
The visual acuity was stable in all patients and no systemic
or ocular side effects were observed during the study period.
Recurrence was not observed in any patient for a follow-up
period of 6 months.
Discussion
Bevacizumab, which is a full-length immunoglobulin, has
a 12-nm-long Y-shaped configuration with a molecular
weight of 149 kDa. Its three arms are *3.5 nm in diameter.
Topical administration of full-length immunoglobulins is
typically considered ineffective because such molecules are
too large to penetrate the intact cornea. However, the clin-
ical effectiveness of topical bevacizumab in the treatment of
corneal NV, which has been shown before,16–19 indirectly
implies that topical bevacizumab can go through the epi-
thelial barrier in patients with ocular inflammation and
corneal NV, which may affect the integrity of the epithelial
barrier. In the light of these previous studies, we aimed to
evaluate the efficacy of topical bevacizumab treatment in
patients with OSSN.
Subconjunctival anti-VEGF agents have been used for the
treatment of OSSN previously. Teng et al. evaluated the
efficacy of subconjunctival ranibizumab for the treatment of
refractory squamous cell carcinoma of the conjunctiva with
corneal extension in 4 patients.13 Their results revealed that
ranibizumab can decrease the size and vascularity of the
tumors; however, complete disappearance of the tumor did
not occur in any of the cases. Finger and Chin evaluated the
safety, tolerability, and efficacy of subconjunctival ranibi-
zumab in 5 patients with recurrent squamous cell carcinoma
of the conjunctiva and cornea with 16–24 injections and
FIG. 1. Patient 1 before (A)
and after (B) topical bev-
acizumab treatment. Reduction
in the tumor size was observed
both in the conjunctival and
corneal portions of the tumor.
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reported a clinically defined complete response in three
cases.14 They stated that anti-VEGF chemotherapy may
offer a new strategy, complement excision and cryotherapy,
or provide an alternative to radiation and/or exenteration.
The first case report evaluating the intralesional use of
bevacizumab as an adjunctive therapy in a patient with
OSSN stated that no significant change was observed in the
tumor grossly and histologically.15 In another recent
study,12 efficacy and safety of subconjunctival bevacizumab
were evaluated in 10 eyes with primary OSSN. Two sub-
conjunctival injections were given with a 2-week interval.
The mean tumor area was reduced by 25%– 5.65%, 2 weeks
after the first injection, and by 42%– 33%, 2 weeks after the
second injection. Reduction in the tumor size occurred
mainly in the conjunctival portion of the tumors and the
corneal portions remained approximately stable. In 2 cases
with exclusive conjunctival involvement, complete resolu-
tion of the tumor was observed and confirmed with
impression cytology. In our study, the mean reduction ob-
served in the lesion area was higher compared with the re-
sults of this study [43% – 24.2% (range, 20%–71%;
P = 0.026) in the first month and 68%– 29.7% (range, 42%–
100%; P= 0.026) in the second month]. Moreover, reduction
in the tumor size was observed both in the conjunctival and
corneal portions of the tumors.
To our knowledge, this is the first study evaluating topical
bevacizumab for the treatment of OSSN. Treatment of OSSN
using topical therapy has the advantage of treating the whole
ocular surface, including subclinical atypical cells, and of
avoiding injection-related complications, including pain and
subconjunctival hemorrhage.Most recently, Kim et al. showed
that topically administered bevacizumab was more long-
standing than a subconjunctivally injected drug in inhibiting
corneal neovascularization.18 Moreover, the antiangiogenic
effect of topically administered and subconjunctivally injected
bevacizumab did not differ at 1 week after treatment in 2
previous comparative studies.19,20 The superior or equal effi-
cacy of topically applied bevacizumab with subconjunctival
bevacizumab might be due to the altered permeability of the
diseased cornea to bevacizumab or the the limbal penetration
of antibodies, as occurs with other peptides or F(abs).21
Topical interferon a-2b (IFNa-2b) is currently the main-
stay of medical treatment of OSSN because it is relatively
nontoxic to the ocular surface when compared with MMC
and 5-FU.5 It can be used in the form of subconjunctival
injections or topical administration, as well as a combination
of these.5,22–24 In a recent study evaluating the efficacy of
topical IFNa-2b for the treatment of OSSN, the mean tumor
surface area reduction was 58% in the first 3 months of
therapy.24 This is similar to the 68% reduction in the second
month with topical bevacizumab, observed in the current
study. However, some side effects were observed relating to
the use of topical IFNa-2b, including conjunctival hyper-
emia, follicular hypertrophy, giant papillary conjunctivitis,
irritation, corneal epithelial defect, and flu-like symptoms,
which resolved within 1 month of discontinuation of topical
therapy.24 Although the duration of therapy was shorter in
our study, we did not observe any ocular or systemic ad-
verse effects with the use of topical bevacizumab for 2
months. The major disadvantage of topical IFNa-2b is the
high cost when compared with other chemotherapeutic op-
tions for OSSN.
It is known that VEGF is an important neurotrophic growth
factor. Hence, anti-VEGF therapies might have several side
effects on the ocular surface. However, in an experimental
study analyzing the safety profile of VEGF-A neutralization
at the ocular surface, no significant side effects were observed
on normal corneal epithelial wound healing, normal corneal
integrity, or normal nerve fiber density.25 Topical bev-
acizumab is a generally well-tolerated treatment. No side
effects were observed in the literature with 5mg/mL topical
bevacizumab treatment up to 12 months used for different
corneal neovascular diseases.26 However, the possible dose-
dependent inhibitory effect on corneal wound healing should
be kept in mind and care should be taken in patients with
epithelial defects and neurotrophic keratopathy. In our study,
we did not observe any ocular or systemic adverse effects
with a dose of 5mg/mL administered 4 times daily for 8
weeks.
As a result, topical bevacizumab is effective as a neoad-
juvant therapy combined with surgical excision for the
treatment of OSSN. It may be used before surgery to decrease
the size of the excision. Excision may be unnecessary in re-
sponsive patients. In the present study, the treatment was
effective as a neoadjuvant therapy in 66.7% of the cases that
required surgical excision at the end of the topical treatment
period and it was effective as a primary and sole therapy in
33.3% of our cases. Topical treatment also seems superior to
subconjunctival administration, especially for the treatment
of the corneal portion of the tumor. This might be due to the
larger treatment area achieved by topical administration. The
combination of topical and subconjunctival bevacizumab
should be considered for future research in a larger group of
patients.
FIG. 2. Patient 2 before
(A) and after (B) topical bev-
acizumab treatment. Surgical
treatment was not necessary
due to complete disappearance
of the tumor, which was con-
firmed by impression cytology.
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Since recurrence of OSSN can occur even years after
treatment, follow-up is of high importance in continuing to
evaluate the efficacy and side effects of various therapies. In
our study, recurrence was not observed in any patient during
a follow-up period of 6 months. In 4 of the 6 cases, this
could be attributed to surgical resection in addition to or in
lieu of treatment with topical bevacizumab as well. Com-
binations of various chemotherapeutic agents as well as
surgical therapy may be needed in the long-term treatment
of OSSN. Topical bevacizumab therapy was combined with
surgical excision in 66.7% of our cases as well. Further
studies with a longer follow-up duration, different bev-
acizumab concentrations, and a larger number of patients,
including histology experiments to explain the mechanism
of action of the treatment drug, are needed to determine the
safety and efficacy of topical bevacizumab treatment for
OSSN.
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